PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Eric Parker, Sr. Director, Merck to Speak at Neurodegeneration Event September 22-23 in San Francisco - Eric Parker, Senior Director and Site Lead, Neuroscience at Merck will give a featured presentation at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC
Eric Parker, Sr. Director, Merck to Speak at Neurodegeneration Event September 22-23 in San Francisco

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/06/16 - Eric Parker, Senior Director and Site Lead, Neuroscience at Merck will give a featured presentation at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Eric Parker, Senior Director and Site Lead, Neuroscience at Merck will give a featured presentation on “Getting to First BACE: Development of BACE Inhibitors for the Treatment of Alzheimer's Disease” at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.

Eric Parker will review the development of the first small molecule BACE inhibitors, with a particular focus on the efficacy and potential for mechanism-based side effects associated with this approach.

Benefits of Eric Parker’s presentation:

• Chronicles the steps involved in the development of the first potent, small molecule inhibitors of BACE.
• Highlights the importance of close collaboration between chemists, structural biologists, pharmacologists, DMPK, etc. in protease inhibitor drug development.
• Describes a large body of internal work aimed at assessing potential mechanism-based side effects of BACE inhibition, including addressing several literature reports describing various phenotypes of BACE1 and BACE2 knockout mice.

Eric M. Parker oversees all neuroscience drug discovery efforts at the Merck Kenilworth, NJ site. Dr. Parker has more than 20 years of experience in drug discovery and development in the areas of neurodegenerative disease, psychiatric disease, pain, obesity/metabolic disease, oncology and urology. Prior to joining MRL in 2009, Dr. Parker worked at the Schering-Plough Research Institute and the Bristol-Myers Squibb Pharmaceutical Research Institute. He has published over 75 scientific articles and lectures extensively on the work of his group.

The 5th Neurodegenerative Conditions Research and Development Conference will discuss the latest breakthroughs, new drug targets, new models, the development of new biomarkers, imaging modalities, and several other novel developments and therapeutics to combat neurodegenerative conditions.

The sessions for the conferences are:

Plenary Keynote Session
• Session I: Biomarkers: Translation from Discovery to Clinical
• Session II: Novel Therapeutic Targets and Approaches in Neurodegenerative Condition
• Session III: Stem Cell Therapy in CNS
• Session IV: Case Studies in the Preclinical and Clinical Space
• Session V: Novel Therapeutic Targets and Approaches in Alzheimer's Disease
• Session VI: Protein Misfolding and Aggregation

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Eric Parker, Sr. Director, Merck to Speak at Neurodegeneration Event September 22-23 in San Francisco

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)